Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye - Full Text View

Purpose

This is a multicenter evaluation of the effects of the cataract extraction and limbal relaxing incisions (LRI) on corneal sensation and dry eye signs and symptoms.

Condition	Intervention
Dry Eye	Procedure: Cataract Surgery and Limbal relaxing incision


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cataract

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:

The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
The percentage of subjects at month 3 with corneal sensitivity < 50 mm at any of the locations measured. Corneal sensitivity is evaluated by using a nylon filament to measure the capability of the cornea (clear front portion of the eye) to respond to touch. The longest filament length at which a minimum of the 3 out of 5 stimulus applications produce a positive response from the subject was the corneal touch threshold (sensitivity). Measurements were taken at 5 different locations in each cornea.

Secondary Outcome Measures:

Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
Change from baseline in OSDI total score at month 3. The OSDI is a 12-question survey for subjects to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.
Change From Baseline in Corneal Staining at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
Change from baseline in corneal staining at month 3. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0= no staining, 5 = severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A positive number change from baseline represents an increase in corneal staining (worsening of dry eye).
Change From Baseline in Conjunctival Staining at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
Change from baseline in conjunctival staining severity score at month 3. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0= no staining, 5= severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement)
Change From Baseline in Tear Break-Up Time at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
Change from baseline in tear break-up time (TBUT) at month 3. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A negative number change from baseline indicates a decrease in TBUT (worsening).
Change From Baseline in Schirmer's Test at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
Change from baseline in Schirmer's Test result at month 3. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement).


Enrollment:	32
Study Start Date:	May 2010
Study Completion Date:	December 2010
Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Patients with cataract and corneal astigmatism Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)	Procedure: Cataract Surgery and Limbal relaxing incision Cataract extraction and limbal-relaxing incisions

Eligibility


Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients undergoing cataract extraction and limbal relaxing incision

Criteria

Inclusion Criteria:

Patient scheduled to undergo clear corneal cataract extraction with planned limbal relaxing incision for correction of a corneal astigmatism

Exclusion Criteria:

Uncontrolled systemic disease
Have undergone refractive surgery or any surgery involving a limbal or corneal incision
Use of topical cyclosporine (Restasis) within three months of baseline/randomization visit
Temporary or permanent occlusion of the lacrimal puncta

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01161771

Locations


United States, New York

Long Island, New York, United States

Sponsors and Collaborators

Allergan

Investigators


Study Director:	Medical Director	Allergan

More Information

No publications provided


Responsible Party:	Allergan
ClinicalTrials.gov Identifier:	NCT01161771 History of Changes
Other Study ID Numbers:	MA-RES-09-004
Study First Received:	July 6, 2010
Results First Received:	December 13, 2011
Last Updated:	July 17, 2012
Health Authority:	United States: Institutional Review Board

ClinicalTrials.gov processed this record on March 02, 2015